Stereotactic Body Radiotherapy in Patients with Previous Pneumonectomy: Safety and Efficacy Robert Thompson, MD, Meredith Giuliani, MBBS, Mei Ling Yap,

Slides:

Advertisements

Similar presentations

Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review David.

Advertisements

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Jeffrey Bradley, MD Journal of Thoracic Oncology

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy Shankar Siva, MBBS, FRANZCR, Brent Chesson, BAppSc.

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer Wolf Köster, MD, Andrea Heider, MD, Norbert.

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization

Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1–Negative Metastatic Squamous Cell Carcinoma of the Lung Zhigang.

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer?

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Tumor Regression and Positional Changes in Non-small Cell Lung Cancer During Radical Radiotherapy Gerald Lim, MD, Andrea Bezjak, MD, CM, MSc, Jane Higgins,

Stereotactic Radiotherapy for Pulmonary Oligometastases: A Systematic Review Shankar Siva, MBBS, Michael MacManus, MD, MRCP, FRCR, FRANZCR, David Ball,

Predicting Radiation Esophagitis Using 18F-FDG PET During Chemoradiotherapy for Locally Advanced Non–Small Cell Lung Cancer Qurrat Mehmood, MBChB., Alexander.

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

The Moth-Eaten Lung Journal of Thoracic Oncology

Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm Hilâl Tekatli, MD, Saar van ’t Hof, MD, Esther.

Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer: What We Have Learned Joe Y. Chang, MD, PhD, Andrea Bezjak,

Tracheoesophageal Fistula Associated with Bevacizumab 21 Months after Completion of Radiation Therapy Elizabeth Gore, MD, Adam Currey, MD, Nicholas Choong,

Radiological Changes After Stereotactic Radiotherapy for Stage I Lung Cancer Max Dahele, MBChB, MSc, David Palma, MD, Frank Lagerwaard, MD, PhD, Ben Slotman,

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Evaluation of the Recommended Dose and Efficacy of Amrubicin as Second- and Third- Line Chemotherapy for Small Cell Lung Cancer Satoshi Igawa, MD, PhD,

Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome.

Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist Kitty Huang, MSc, MDCM, David A. Palma,

Toxicities of Organs at Risk in the Mediastinal and Hilar Regions Following Stereotactic Body Radiotherapy for Centrally Located Lung Tumors Shuichi.

Kiran Devisetty, MD, Joseph K. Salama, MD Journal of Thoracic Oncology

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Chest Wall Pain and Rib Fracture after Stereotactic Radiotherapy for Peripheral Non- small Cell Lung Cancer Jon-Paul J. Voroney, PhD, MD, Andrew Hope,

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Treatment of the Elderly When Cure is the Goal: The Influence of Age on Treatment Selection and Efficacy for Stage III Non-small Cell Lung Cancer Linda.

Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival after Stereotactic Body Radiation Therapy for Lung Cancer Nami.

“The Best-Laid Plans … Often go Awry …”

Imaging Requirements in the Practice of Pulmonary Metastasectomy

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Incidence and Risk Factors for Chest Wall Toxicity After Risk-Adapted Stereotactic Radiotherapy for Early-Stage Lung Cancer Eva M. Bongers, MD, Cornelis.

Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non–Small Cell Lung Cancer: A Phase I Study Kristin A. Higgins,

Stereotactic Body Radiation Therapy for Primary Lung Cancers >3 Centimeters John J. Cuaron, MD, Ellen D. Yorke, PhD, Amanda Foster, BA, Meier Hsu, MS,

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

Nicholas Trakul, MD, PhD, Jeremy P

Jeffrey Bradley, MD Journal of Thoracic Oncology

Iris Metastasis from Small-Cell Lung Cancer

Patterns of Local and Nodal Failure in Malignant Pleural Mesothelioma After Extrapleural Pneumonectomy and Photon-Electron Radiotherapy Vishal Gupta,

Clinical Relevance of Our Multimodality Prognostic Score

It’s All in the “Swerve of the Curve”

Stereotactic Body Radiation Therapy for the Treatment of Primary Cardiac Angiosarcoma Causing Hemodynamic Instability Prashant Gabani, MD, Benjamin W.

Pulmonary Resection for Metastases from Colorectal Cancer

Gaurav Marwaha, MD, Kevin L. Stephans, MD, Neil M

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Pulmonary Atelectasis after Stereotactic Ablative Radiotherapy for a Central Lung Tumor Sashendra Senthi, MBChB, FRANZCR, Eric F Ullmann, MD, Suresh.

International Thymic Malignancies Interest Group: A Way Forward

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Todd J. Carpenter, MD, Kenneth E. Rosenzweig, MD

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Local Control and Toxicity of Adaptive Radiotherapy Using Weekly CT Imaging: Results from the LARTIA Trial in Stage III NSCLC Sara Ramella, MD, Michele.

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi.

Presentation transcript:

Stereotactic Body Radiotherapy in Patients with Previous Pneumonectomy: Safety and Efficacy Robert Thompson, MD, Meredith Giuliani, MBBS, Mei Ling Yap, MD, Soha Atallah, MD, Lisa W. Le, MSc, Alexander Sun, MD, Anthony Brade, MD, B.C. John Cho, MD, Andrea Bezjak, MD, Andrew Hope, MD Journal of Thoracic Oncology Volume 9, Issue 6, Pages 843-847 (June 2014) DOI: 10.1097/JTO.0000000000000159 Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Images of the lung nodule pre- and post-SBRT and the radiation plan. (A) The pretreatment computed tomography thorax demonstrating the solitary pulmonary nodule. B) The radiotherapy plan. The red area is the gross tumor volume, the green area is the planning target volume, the blue line is the 4560 cGy isodose line (95% of the prescription dose), the purple line is the 2000 cGy isodose line and the teal line is the 1000 cGy isodose line. C) The 18 month posttreatment computed tomography thorax demonstrating resolution of the pulmonary nodule. Journal of Thoracic Oncology 2014 9, 843-847DOI: (10.1097/JTO.0000000000000159) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Kaplan-Meier plot of cause-specific survival. Journal of Thoracic Oncology 2014 9, 843-847DOI: (10.1097/JTO.0000000000000159) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Kaplan-Meier plot of overall survival. Journal of Thoracic Oncology 2014 9, 843-847DOI: (10.1097/JTO.0000000000000159) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions